BrightGene Bio Medical Technology C Net Asset Quality Index
BrightGene Bio Medical Technology C net asset quality index. BrightGene Bio Medical Technology C (688166) has a Net Asset Quality Index of 48.0% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.38 Billion minus total liabilities of CN¥2.80 Billion yields net assets of CN¥2.59 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 688166 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of BrightGene Bio Medical Technology C (2016–2024)
Net asset quality index of BrightGene Bio Medical Technology C from 2016 to 2024. This chart shows how BrightGene Bio Medical Technology C's Net Asset Quality Index has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the index stands at 48.0%, representing net assets of CN¥2.59 Billion against total assets of CN¥5.38 Billion CNY. See 688166 total equity for net asset value and shareholders' equity analysis.
BrightGene Bio Medical Technology C Net Asset Quality Index by Year (2016–2024)
BrightGene Bio Medical Technology C net asset quality index by year from 2016 to 2024. The table below presents the year-by-year Net Asset Quality Index for BrightGene Bio Medical Technology C from 2016 to 2024, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see BrightGene Bio Medical Technology C market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 47.2% | CN¥2.44 Billion | CN¥5.16 Billion | CN¥2.73 Billion | ▼ -0.8 pp |
| 2023 | 48.0% | CN¥2.42 Billion | CN¥5.03 Billion | CN¥2.61 Billion | ▼ 0.0 pp |
| 2022 | 48.1% | CN¥2.24 Billion | CN¥4.66 Billion | CN¥2.42 Billion | ▼ -10.6 pp |
| 2021 | 58.6% | CN¥1.74 Billion | CN¥2.97 Billion | CN¥1.23 Billion | ▼ -19.7 pp |
| 2020 | 78.4% | CN¥1.43 Billion | CN¥1.83 Billion | CN¥395.23 Million | ▼ -14.0 pp |
| 2019 | 92.4% | CN¥1.31 Billion | CN¥1.42 Billion | CN¥108.21 Million | ▲ +4.4 pp |
| 2018 | 88.0% | CN¥772.85 Million | CN¥878.37 Million | CN¥105.52 Million | ▲ +3.0 pp |
| 2017 | 85.0% | CN¥446.02 Million | CN¥524.92 Million | CN¥78.89 Million | ▲ +27.7 pp |
| 2016 | 57.3% | CN¥220.15 Million | CN¥384.19 Million | CN¥164.05 Million | — |